## Michel Boussinesq

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/627901/publications.pdf

Version: 2024-02-01

120 papers 29,157 citations

66343 42 h-index 20358 116 g-index

122 all docs 122 docs citations

122 times ranked 44582 citing authors

#	Article	IF	CITATIONS
1	Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial. Clinical Infectious Diseases, 2022, 75, 19-27.	5.8	13
2	Impact of Semi-Annual Albendazole on Lymphatic Filariasis and Soil-Transmitted Helminth Infection: Parasitological Assessment after 14 Rounds of Community Treatment. American Journal of Tropical Medicine and Hygiene, 2022, 106, 729-731.	1.4	1
3	Historical overview and geographical distribution of neglected tropical diseases amenable to preventive chemotherapy in the Republic of the Congo: A systematic review. PLoS Neglected Tropical Diseases, 2022, 16, e0010560.	3.0	O
4	Results from two cohort studies in Central Africa show that clearance of Wuchereria bancrofti infection after repeated rounds of mass drug administration with albendazole alone is closely linked to individual adherence. Clinical Infectious Diseases, 2021, 73, e176-e183.	5.8	7
5	Limitations of PCR detection of filarial DNA in human stools from subjects non-infected with soil-transmitted helminths. Parasite, 2021, 28, 47.	2.0	2
6	Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World. PLoS Neglected Tropical Diseases, 2021, 15, e0009354.	3.0	28
7	A strong effect of individual compliance with mass drug administration for lymphatic filariasis on sustained clearance of soil-transmitted helminth infections. Parasites and Vectors, 2021, 14, 310.	2.5	O
8	Effect of Lymphatic Filariasis and Hookworm Infection on Pregnancy Course and Outcome in Women Living in the Democratic Republic of the Congo. American Journal of Tropical Medicine and Hygiene, 2021, 104, 2074-2081.	1.4	O
9	Unusual Localization of Blood-Borne <i>Loa loa</i> Microfilariae in the Skin Depends on Microfilarial Density in the Blood: Implications for Onchocerciasis Diagnosis in Coendemic Areas. Clinical Infectious Diseases, 2021, 72, S158-S164.	5.8	6
10	Epilepsy in the Sanagaâ€Mbam valley, an onchocerciasisâ€endemic region in Cameroon: electroclinical and neuropsychological findings. Epilepsia Open, 2021, 6, 513-527.	2.4	6
11	Feasibility of Onchocerciasis Elimination Using a "Test-and-not-treat―Strategy in <i>Loa loa</i> Co-endemic Areas. Clinical Infectious Diseases, 2021, 72, e1047-e1055.	5.8	6
12	Knowledge/perception and attitude/practices of populations of two first-line communities of the Centre Region of Cameroon regarding onchocerciasis and black fly nuisance and bio-ecology. Parasites and Vectors, 2021, 14, 546.	2.5	2
13	Onchocerca volvulus transmission in the Mbam valley of Cameroon following 16Âyears of annual community-directed treatment with ivermectin, and the description of a new cytotype of Simulium squamosum. Parasites and Vectors, 2021, 14, 563.	2.5	12
14	A Test-and-Not-Treat Strategy for Onchocerciasis Elimination in Loa loa–coendemic Areas: Cost Analysis of a Pilot in the Soa Health District, Cameroon. Clinical Infectious Diseases, 2020, 70, 1628-1635.	5.8	14
15	Projected Number of People With Onchocerciasis–Loiasis Coinfection in Africa, 1995 to 2025. Clinical Infectious Diseases, 2020, 70, 2281-2289.	5.8	25
16	Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study. Lancet Infectious Diseases, The, 2020, 20, 102-109.	9.1	34
17	Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa. EClinicalMedicine, 2020, 28, 100582.	7.1	20
18	Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually. Parasites and Vectors, 2020, 13, 258.	2.5	11

#	Article	IF	CITATIONS
19	Effects of an injectable long-acting formulation of ivermectin on <i>Onchocerca ochengi</i> in zebu cattle. Parasite, 2020, 27, 36.	2.0	7
20	Performance of two serodiagnostic tests for loiasis in a Non-Endemic area. PLoS Neglected Tropical Diseases, 2020, 14, e0008187.	3.0	13
21	Detection of DNA of filariae closely related to Mansonella perstans in faecal samples from wild non-human primates from Cameroon and Gabon. Parasites and Vectors, 2020, 13, 313.	2.5	11
22	Community-based door to door census of suspected people living with epilepsy: empowering community drug distributors to improve the provision of care to rural communities in Cameroon. BMC Public Health, 2020, 20, 871.	2.9	5
23	A Second Population-Based Cohort Study in Cameroon Confirms the Temporal Relationship Between Onchocerciasis and Epilepsy. Open Forum Infectious Diseases, 2020, 7, ofaa206.	0.9	47
24	The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo. PLoS Neglected Tropical Diseases, 2020, 14, e0008322.	3.0	15
25	Safety of high-dose ivermectin: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2020, 75, 827-834.	3.0	93
26	Atypical Clinical Manifestations of Loiasis and Their Relevance for Endemic Populations. Open Forum Infectious Diseases, 2019, 6, ofz417.	0.9	27
27	Impact of 19Âyears of mass drug administration with ivermectin on epilepsy burden in a hyperendemic onchocerciasis area in Cameroon. Parasites and Vectors, 2019, 12, 114.	2.5	22
28	Risk factors for lymphatic filariasis in two villages of the Democratic Republic of the Congo. Parasites and Vectors, 2019, 12, 162.	2.5	11
29	Effect of a Single Standard Dose (150–200 μg/kg) of Ivermectin on <i>Loa loa</i> Microfilaremia: Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2019, 6, ofz019.	0.9	15
30	Genomic Epidemiology in Filarial Nematodes: Transforming the Basis for Elimination Program Decisions. Frontiers in Genetics, 2019, 10, 1282.	2.3	29
31	A new powerful drug to combat river blindness. Lancet, The, 2018, 392, 1170-1172.	13.7	16
32	Familial Aggregation and Heritability of Loa loa Microfilaremia. Clinical Infectious Diseases, 2018, 66, 751-757.	5.8	17
33	The Population Biology and Transmission Dynamics of Loa loa. Trends in Parasitology, 2018, 34, 335-350.	3.3	47
34	Report of the first international workshop on onchocerciasis-associated epilepsy. Infectious Diseases of Poverty, 2018, 7, 23.	3.7	30
35	Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13Âyears of ivermectin. Infectious Diseases of Poverty, 2018, 7, 114.	3.7	52
36	The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study. Lancet Infectious Diseases, The, 2018, 18, 1278-1286.	9.1	114

#	Article	IF	Citations
37	Operationalization of the test and not treat strategy to accelerate the elimination of onchocerciasis and lymphatic filariasis in Central Africa. International Health, 2018, 10, i49-i53.	2.0	16
38	How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control. Clinical Infectious Diseases, 2018, 66, S267-S274.	5.8	55
39	Alternative treatment strategies to accelerate the elimination of onchocerciasis. International Health, 2018, 10, i40-i48.	2.0	89
40	Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo. Lancet Infectious Diseases, The, 2017, 17, 763-769.	9.1	37
41	Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness. Clinical Infectious Diseases, 2017, 65, 2026-2034.	5.8	55
42	A Test-and-Not-Treat Strategy for Onchocerciasis in <i>Loa loa</i> –Endemic Areas. New England Journal of Medicine, 2017, 377, 2044-2052.	27.0	135
43	Excess mortality associated with loiasis: a retrospective population-based cohort study. Lancet Infectious Diseases, The, 2017, 17, 108-116.	9.1	70
44	Helminthic Diseases: Onchocerciasis and Loiasis. , 2017, , 576-587.		8
45	Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity. PLoS Neglected Tropical Diseases, 2017, 11, e0005816.	3.0	87
46	A multi-center field study of two point-of-care tests for circulating Wuchereria bancrofti antigenemia in Africa. PLoS Neglected Tropical Diseases, 2017, 11, e0005703.	3.0	19
47	Microfilariae Classification Using Multiple Classifiers for Color and Shape Features. Open Engineering, 2016, 6, .	1.6	1
48	Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment. Parasites and Vectors, 2016, 9, 581.	2.5	59
49	Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in West Africa. PLoS Neglected Tropical Diseases, 2016, 10, e0004328.	3.0	59
50	Positivity of Antigen Tests Used for Diagnosis of Lymphatic Filariasis in Individuals Without Wuchereria bancrofti Infection But with High Loa loa Microfilaremia. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1417-1423.	1.4	48
51	Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infectious Diseases of Poverty, 2016, 5, 66.	3.7	125
52	Measurement of Circulating Filarial Antigen Levels in Human Blood with a Point-of-Care Test Strip and a Portable Spectrodensitometer. American Journal of Tropical Medicine and Hygiene, 2016, 94, 1324-1329.	1.4	30
53	Familial Aggregation and Heritability of <i>Wuchereria bancrofti </i> Infection. Journal of Infectious Diseases, 2016, 214, 587-594.	4.0	7
54	Analysis of Nematode Motion Using an Improved Light-Scatter Based System. PLoS Neglected Tropical Diseases, 2015, 9, e0003523.	3.0	8

#	Article	IF	Citations
55	The Impact of Two Semiannual Treatments with Albendazole Alone on Lymphatic Filariasis and Soil-Transmitted Helminth Infections: A Community-Based Study in the Republic of Congo. American Journal of Tropical Medicine and Hygiene, 2015, 92, 959-966.	1.4	30
56	Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope. Science Translational Medicine, 2015, 7, 286re4.	12.4	184
57	Reproductive Status of Onchocerca volvulus after Ivermectin Treatment in an Ivermectin-Na $ ilde{A}^-$ ve and a Frequently Treated Population from Cameroon. PLoS Neglected Tropical Diseases, 2014, 8, e2824.	3.0	50
58	The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases. PLoS Neglected Tropical Diseases, 2014, 8, e2865.	3.0	796
59	Imported loiasis in Italy: An analysis of 100 cases. Travel Medicine and Infectious Disease, 2014, 12, 713-717.	3.0	21
60	Absence of an Association Between Plasmodium falciparum Infection and Post-Ivermectin Loa-Related Non-Neurologic Serious Adverse Events. American Journal of Tropical Medicine and Hygiene, 2014, 90, 335-338.	1.4	4
61	A case study of risk factors for lymphatic filariasis in the Republic of Congo. Parasites and Vectors, 2014, 7, 300.	2.5	26
62	Impact of repeated ivermectin treatments against onchocerciasis on the transmission of loiasis: an entomologic evaluation in central Cameroon. Parasites and Vectors, 2013, 6, 283.	2.5	17
63	Case-control Studies on the Relationship between Onchocerciasis and Epilepsy: Systematic Review and Meta-analysis. PLoS Neglected Tropical Diseases, 2013, 7, e2147.	3.0	69
64	Onchocerciasis: The Pre-control Association between Prevalence of Palpable Nodules and Skin Microfilariae. PLoS Neglected Tropical Diseases, 2013, 7, e2168.	3.0	33
65	Dynamics of Onchocerca volvulus Microfilarial Densities after Ivermectin Treatment in an Ivermectin-naÃ-ve and a Multiply Treated Population from Cameroon. PLoS Neglected Tropical Diseases, 2013, 7, e2084.	3.0	43
66	Semi-Quantitative Scoring of an Immunochromatographic Test for Circulating Filarial Antigen. American Journal of Tropical Medicine and Hygiene, 2013, 89, 916-918.	1.4	27
67	Significant Association between Epilepsy and Presence of Onchocercal Nodules: Case-Control Study in Cameroon. American Journal of Tropical Medicine and Hygiene, 2012, 86, 557-557.	1.4	19
68	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
69	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
70	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2224-2260.	13.7	9,397
71	Single nucleotide polymorphisms in $\hat{l}^2$ -tubulin selected in Onchocerca volvulus following repeated ivermectin treatment: Possible indication of resistance selection. Molecular and Biochemical Parasitology, 2012, 185, 10-18.	1.1	26
72	Loiasis: New Epidemiologic Insights and Proposed Treatment Strategy. Journal of Travel Medicine, 2012, 19, 140-143.	3.0	41

#	Article	IF	Citations
73	Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin. Acta Tropica, 2011, 120, S91-S99.	2.0	13
74	Loiasis with Peripheral Nerve Involvement and Spleen Lesions. American Journal of Tropical Medicine and Hygiene, 2011, 84, 733-737.	1.4	10
75	Erythropoietin for treating post-ivermectin Loa-related serious adverse events?. Trends in Parasitology, 2010, 26, 4-5.	<b>3.</b> 3	3
76	Analysis of the mdr-1 Gene in Patients Co-Infected with Onchocerca volvulus and Loa loa Who Experienced a Post-Ivermectin Serious Adverse Event. American Journal of Tropical Medicine and Hygiene, 2010, 83, 28-32.	1.4	52
77	A Controlled Trial to Assess the Effect of Quinine, Chloroquine, Amodiaquine, and Artesunate on Loa loa Microfilaremia. American Journal of Tropical Medicine and Hygiene, 2010, 82, 379-385.	1.4	12
78	Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16716-16721.	7.1	77
79	Loa loa Microfilarial Periodicity in Ivermectin-Treated Patients: Comparison Between Those Developing and Those Free of Serious Adverse Events. American Journal of Tropical Medicine and Hygiene, 2009, 81, 1056-1061.	1.4	35
80	Head nodding syndrome and river blindness: A parasitologic perspective. Epilepsia, 2009, 50, 2325-2326.	5.1	23
81	Epilepsy in Onchocerciasis Endemic Areas: Systematic Review and Meta-analysis of Population-Based Surveys. PLoS Neglected Tropical Diseases, 2009, 3, e461.	3.0	130
82	Lymphatic Vascularisation and Involvement of Lyve-1+ Macrophages in the Human Onchocerca Nodule. PLoS ONE, 2009, 4, e8234.	2.5	39
83	P-glycoprotein-like protein, a possible genetic marker for ivermectin resistance selection in Onchocerca volvulus. Molecular and Biochemical Parasitology, 2008, 158, 101-111.	1.1	75
84	Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2008, 8, 310-322.	9.1	177
85	Intensity of Intestinal Infection with Multiple Worm Species Is Related to Regulatory Cytokine Output and Immune Hyporesponsiveness. Journal of Infectious Diseases, 2008, 197, 1204-1212.	4.0	104
86	Encephalopathy after Ivermectin Treatment in a Patient Infected with Loa Loa and Plasmodium spp American Journal of Tropical Medicine and Hygiene, 2008, 78, 546-551.	1.4	39
87	Onchocerciasis, Cysticercosis, and Epilepsy. American Journal of Tropical Medicine and Hygiene, 2008, 79, 643-644.	1.4	14
88	Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. American Journal of Tropical Medicine and Hygiene, 2008, 78, 546-51.	1.4	20
89	Onchocerciasis, cysticercosis, and epilepsy. American Journal of Tropical Medicine and Hygiene, 2008, 79, 643-4; author reply 644-5.	1.4	8
90	African Programme for Onchocerciasis Control (APOC): sociological study in three foci of central Africa before the implementation of treatments with ivermectin (Mectizan $\hat{A}^{\otimes}$ ). Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 674-679.	1.8	10

#	Article	IF	Citations
91	Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (â^1/425Î1/4g/kg) versus current standard dose (150Î1/4g/kg). Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 777-785.	1.8	28
92	Where next with Loa loa encephalopathy? Data are badly needed. Trends in Parasitology, 2007, 23, 237-238.	3.3	20
93	Genetic Selection of Low Fertile Onchocerca volvulus by Ivermectin Treatment. PLoS Neglected Tropical Diseases, 2007, 1, e72.	3.0	97
94	A possible case of spontaneous Loa loa encephalopathy associated with a glomerulopathy. Parasites and Vectors, 2006, 5, 6.	1.3	32
95	Evaluation of the diethylcarbamazine patch to evaluate onchocerciasis endemicity in Central Africa.  Tropical Medicine and International Health, 2006, 12, 061030012640002-???.	2.3	29
96	Onchocerciasis-related epilepsy? Prospects at a time of uncertainty. Trends in Parasitology, 2006, 22, 17-20.	3.3	26
97	What are the mechanisms associated with post-ivermectin serious adverse events?. Trends in Parasitology, 2006, 22, 244-246.	3.3	27
98	River Blindness: A Success Story under Threat?. PLoS Medicine, 2006, 3, e371.	8.4	194
99	Allergen-specific IgE and IgG4 are markers of resistance and susceptibility in a human intestinal nematode infection. Microbes and Infection, 2005, 7, 990-996.	1.9	104
100	A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 279-289.	1.8	28
101	Associations between filarial and gastrointestinal nematodes. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 301-312.	1.8	22
102	Human infection patterns and heterogeneous exposure in river blindness. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15265-15270.	7.1	77
103	T Helper Cell Type 2 Responsiveness Predicts Future Susceptibility to Gastrointestinal Nematodes in Humans. Journal of Infectious Diseases, 2004, 190, 1804-1811.	4.0	110
104	Genetic heterogeneity in Loa loa parasites from southern Cameroon: A preliminary study. Parasites and Vectors, 2004, 3, 4.	1.3	7
105	Mapping the distribution of Loa loa in Cameroon in support of the African Programme for Onchocerciasis Control. Parasites and Vectors, 2004, 3, 7.	1.3	57
106	Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 496-504.	1.8	50
107	Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Parasites and Vectors, 2003, 2, S4.	1.3	149
108	Demographic Impact of Epilepsy in Africa: Results of a 10â€year Cohort Study in a Rural Area of Cameroon. Epilepsia, 2003, 44, 956-963.	5.1	81

#	Article	IF	Citations
109	Th2 Cytokines Are Associated with Reduced Worm Burdens in a Human Intestinal Helminth Infection. Journal of Infectious Diseases, 2003, 188, 1768-1775.	4.0	175
110	Age―and Infection Intensity–Dependent Cytokine and Antibody Production in Human Trichuriasis: The Importance of IgE. Journal of Infectious Diseases, 2002, 185, 665-672.	4.0	94
111	Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet, The, 2002, 360, 203-210.	13.7	144
112	A comparison of cellular and humoral immune responses to trichuroid derived antigens in human trichuriasis. Parasite Immunology, 2002, 24, 83-93.	1.5	17
113	Antibody responses in onchocerciasis as a function of age and infection intensity. Parasite Immunology, 2001, 23, 509-516.	1.5	13
114	Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia. Ophthalmic Epidemiology, 2000, 7, 27-39.	1.7	31
115	Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia. Ophthalmic Epidemiology, 2000, 7, 27-39.	1.7	3
116	La résistance de Onchocerca volvulus à livermectine: une éventualité à considérer. Annales De L'Institut Pasteur / Actualités, 1999, 10, 81-91.	0.1	11
117	Population biology of human onchocerciasis. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 809-826.	4.0	95
118	Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet, The, 1997, 350, 18-22.	13.7	554
119	Severe adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areas. Parasitology Today, 1996, 12, 448-450.	3.0	114
120	Longitudinal Survey of Loa loa Filariasis in Southern Cameroon: Long-Term Stability and Factors Influencing Individual Microfilarial Status. American Journal of Tropical Medicine and Hygiene, 1995, 52, 370-375.	1.4	38